Stay up to date on recent advances in oncology nursing and patient care.
Novel ADC Receives FDA Fast Track Designation for Pancreatic Cancer
The novel antibody-drug conjugate EBC-129 has been fast tracked by the FDA for approval in pancreatic ductal adenocarcinoma.
ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment
Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.
Retifanlimab Receives FDA Approval for Advanced Anal Cancer
Retifanlimab has received approval for the frontline treatment of advanced anal cancer from the FDA.
Terri Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium
In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.
Cabozantinib Approved for Unresectable, Advanced/Metastatic epNET and pNET
The FDA approved cabozantinib for use in patients with previously treated unresectable, locally advanced or metastatic, well-differentiated epNETs or pNETs.
Maintenance OSE2101 With Chemo Reaches Primary OS End Point in PDAC
Maintenance treatment with OSE2101 plus FOLFIRI following induction chemotherapy with FOLFIRINOX yielded promising results in patients with advanced/metastatic PDAC.
Relacorilant/Nab-Paclitaxel Is Convenient, Safe in Ovarian Cancer
Neoadjuvant Nivolumab Regimen Improves OS in Resectable NSCLC
Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer
Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care
